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OPEN
ORIGINAL ARTICLE
Subcortical brain volume abnormalities in 2028 individuals
with schizophrenia and 2540 healthy controls via the
ENIGMA consortium
TGM van Erp1,39, DP Hibar2,39, JM Rasmussen1, DC Glahn3,4, GD Pearlson3,4, OA Andreassen5, I Agartz5,6,7, LT Westlye5,8, UK Haukvik5,
AM Dale9,10, I Melle5, CB Hartberg5,6, O Gruber11, B Kraemer11, D Zilles11,12, G Donohoe13,14, S Kelly2,14, C McDonald15, DW Morris13,14,
DM Cannon15, A Corvin14, MWJ Machielsen16, L Koenders16, L de Haan16, DJ Veltman17, TD Satterthwaite18, DH Wolf18, RC Gur18,
RE Gur18, SG Potkin1, DH Mathalon19,20, BA Mueller21, A Preda1, F Macciardi1, S Ehrlich22,23,24, E Walton22, J Hass22, VD Calhoun25,26,
HJ Bockholt25,27,28, SR Sponheim29, JM Shoemaker25, NEM van Haren30, HEH Pol30, RA Ophoff30,31, RS Kahn30, R Roiz-Santiañez32,33,
B Crespo-Facorro32,33, L Wang34,35, KI Alpert34, EG Jönsson5,7, R Dimitrova36, C Bois36, HC Whalley36, AM McIntosh36, SM Lawrie36,
R Hashimoto37, PM Thompson2 and JA Turner25,38 for the ENIGMA Schizophrenia Working Group40
The profile of brain structural abnormalities in schizophrenia is still not fully understood, despite decades of research using brain
scans. To validate a prospective meta-analysis approach to analyzing multicenter neuroimaging data, we analyzed brain MRI scans
from 2028 schizophrenia patients and 2540 healthy controls, assessed with standardized methods at 15 centers worldwide. We
identified subcortical brain volumes that differentiated patients from controls, and ranked them according to their effect sizes.
Compared with healthy controls, patients with schizophrenia had smaller hippocampus (Cohen’s d=− 0.46), amygdala (d=− 0.31),
thalamus (d=− 0.31), accumbens (d=− 0.25) and intracranial volumes (d=− 0.12), as well as larger pallidum (d= 0.21) and lateral
ventricle volumes (d= 0.37). Putamen and pallidum volume augmentations were positively associated with duration of illness and
hippocampal deficits scaled with the proportion of unmedicated patients. Worldwide cooperative analyses of brain imaging data
support a profile of subcortical abnormalities in schizophrenia, which is consistent with that based on traditional meta-analytic
approaches. This first ENIGMA Schizophrenia Working Group study validates that collaborative data analyses can readily be used
across brain phenotypes and disorders and encourages analysis and data sharing efforts to further our understanding of severe
mental illness.
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INTRODUCTION
Achievements based on cooperative analyses of neuroimaging
data in severe mental illness trail those in genetics.1–3 This
manuscript presents a first validation of our approach to
collectively analyze neuroimaging data via the ENIGMA Schizo-
phrenia Working Group.
Individuals with schizophrenia show significant brain morpho-
logical abnormalities, but there is considerable heterogeneity in
the effect sizes and patterns of brain differences across studies.4–11
The study of structural brain abnormalities in schizophrenia can
help us understand its causes, progression and even treatment
effects. Even so, brain differences are influenced by multiple
factors—some with opposing effects. Small studies can yield
findings that conflict or are not subsequently replicated. Here, we
demonstrate a profile of brain abnormalities based on 15
schizophrenia cohorts worldwide, and rank effect size estimates
for subcortical and intracranial brain volume differences between
individuals with schizophrenia and healthy controls. We also
attempt to identify factors that may contribute to effect size
heterogeneity across studies.
Despite early suggestion,6 much collected imaging and
associated data does not reside in electronic databases that are
easily queried for joint analyses and there are no agreed upon
standards for efficient data sharing. Here we report ENIGMA’s first
analysis of schizophrenia brain morphology using harmonized
methods to combine brain volumes across samples. The study
provides a proof of concept that prospective analyses of already
collected data using similar methods can yield robust findings
with sample sizes larger than those achieved via retrospective
meta-analyses of published work.
‘Retrospective’ meta-analyses—or traditional meta-analyses
that pool statistical findings reported in the literature—are
invaluable for summarizing the state of research findings and
identifying possible sources of heterogeneity; they also yield effect
sizes for power calculations. However, in traditional meta-analyses
much of the collected data are not fully explored. For instance,
Haijma et al.11 identified 119 published studies of schizophrenia
that reported on whole brain volumes, but only 9 publications that
reported on occipital lobe gray matter volumes. For subcortical
structures in particular, 87 publications reported hippocampal
volumes, but only 13 reported accumbens volumes. Automated
image analysis software, and increasingly efficient global colla-
borations, now allow for prospective analyses of brain scans
worldwide using standardized methods. Prospective mega-ana-
lyses require the pooling of individual subject data. In contrast,
prospective meta-analyses only require the pooling of specific
summary statistics—computed at each participating center. This is
highly effective even when participants’ consent for individual-
level data sharing was not obtained. The power of this approach
lies in the consistency of the analyses across data sets rather than
the ad hoc aggregation of statistics from the literature. Large-scale
analyses using similar methods across cohorts worldwide can also
be applied across traditional diagnostic boundaries to yield robust
and consistent anatomical fingerprints associated with brain
disorders to help formulate improved diagnostic classifications
based on both brain and behavioral evaluations.
To validate our approach and address the vast heterogeneity of
studies and measures reported, here we estimated and ranked
effect sizes for regional brain volume abnormalities in individuals
with schizophrenia using the same image analysis, quality
assurance and statistical analysis methods across a large
number of independently evaluated samples. We also explored
effects of available demographics (age at onset, duration of
illness, age, chlorpromazine dose equivalents, proportion of
second-generation (atypical), first-generation (typical), both or
no antipsychotic medication, and severity of positive and negative
symptoms) and methodological variables (scanner field strength
and FreeSurfer version) on the effect size estimates across studies.
Based on the largest schizophrenia brain volume meta-analysis
conducted to date,11 we predicted that individuals with schizo-
phrenia would show smaller hippocampus, amygdala, thalamus,
accumbens and intracranial volumes (ICVs), as well as larger




Fifteen worldwide (see Supplementary Figure S1) cross-sectional study
samples12–21 totaling 4568 participants—2028 individuals with schizo-
phrenia and 2540 healthy controls—contributed to the collaborative
analysis of subcortical brain volumes via the ENIGMA Schizophrenia
Working Group (Supplementary Tables S3a and b). The sample-size-
weighted mean age across samples for controls was 31 (range: 23–42)
years and for patients 34 (range: 22–43) years. The control and patient
samples were on average 52% (range: 38–71%) and 69% male (range: 56–
87%). The weighted mean age at onset and duration of illness across the
patient groups were 23 (range: 20–29) and 10 (range: 0.8–20) years. The
weighted mean total PANSS (Positive and Negative Syndrome Scale), SANS
(Scale for the Assessment of Negative Symptoms) and SAPS (Scale for the
Assessment of Positive Symptoms) total scores across the samples were 63
(range: 36–90), 24 (range: 15–33) and 18 (range: 8–41) years. For samples
that recorded current antipsychotic type and dose, the percentage of
patients on second-generation (atypical; 77%), first-generation (typical;
15%), both (3%) or none (5%) was determined and for 11 samples
chlorpromazine dose equivalents were computed based on Woods
(2005; www.scottwilliamwoods.com/files/Equivtext.doc). The size-weighted
mean chlorpromazine dose equivalent across the samples was 436 (range:
276–704). Each study sample was collected with participants’ written
informed consent approved by local Institutional Review Boards. No
individual subject imaging or clinical data were shared among the ENIGMA
institutions.
Image acquisition and processing
Left and right lateral ventricle, thalamus, caudate, putamen, pallidum,
accumbens, hippocampus and amygdala volumes, as well as ICVs, were
obtained with FreeSurfer22,23 (http://surfer.nmr.mgh.harvard.edu) from
high-resolution T1-weighted structural brain scans (Supplementary Tables
S4 and S4a and o). Details on study type (single site or multisite), scanner
vendor/strength/sequence, acquisition parameters and FreeSurfer versions
used are provided in Supplementary Table S3b. For quality control, all
regions of interest (ROIs) with a volume larger or o1.5 times the
interquartile range were identified and visually inspected by overlaying
their segmentations on the subjects’ anatomical images. Only ROI data for
which segmentation was judged accurate upon visual inspection were
subjected to statistical analyses (see Supplementary Figure S2 for ROI
volume histograms).
Statistical meta-analyses
Group differences for each ROI within each sample were examined using
univariate linear regression analysis (R’s linear model function lm)
predicting the mean of left and right subcortical volumes with group
(patient, control). The main analysis (model 1) included sex, age and ICV as
covariates. Secondary models excluded ICV (model 2) or ICV, sex and age
(model 3; uncorrected means model) covariates. The analysis of ICV was
performed with models 2 and 3. Analysis of multiscanner studies (FBIRN,
MCIC) included binary dummy covariates for n− 1 scanners. For each
sample, Cohen’s d effect sizes for each ROI and model were computed
based on the group contrast t-statistics;24 see Supplementary Information
1 for details. Exploratory analyses examined the effect sizes for left and
right hemisphere ROIs separately. Analyses of individual subject data were
performed by the site that contributed the sample, using code created
within the ENIGMA collaboration. Everyone in the working group had
access to statistical results from each site.
Moderator analyses
Meta-regression analyses examined associations between sample demo-
graphics (mean age at onset, duration of illness, age, chlorpromazine dose
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equivalents, proportion of typical, atypical, both or no antipsychotic
medication, as well as severity of positive and negative symptoms) and
methodology (field strength and FreeSurfer version) and effect sizes across
studies. These analyses used a conservative Bonferroni-corrected P-value
threshold (Po0.0056). For exploratory purposes and future hypothesis
generation, we also report on nominally significant findings (Po0.05; two-
tailed, uncorrected).
Power analyses
Sample sizes that achieve 80% power to detect group differences given
the presented effect sizes were calculated based on one-tailed t-tests with
G*Power Version 3.2.1.25
RESULTS
Ranking group differences in terms of their effect sizes
Compared with controls, individuals with schizophrenia showed
significantly smaller hippocampus (mean difference from control
mean: − 4.10%), amygdala (−3.80%), thalamus (−2.74%), accum-
bens (−3.69%) and ICVs (−0.30%), as well as larger pallidum
(+2.28%) and lateral ventricle volumes (+18.24%; see Figure 1 and
Table 1). The biggest patient control effect size was observed
for smaller hippocampus volume (d=− 0.46, P= 4.85 × 10− 14),
followed by larger lateral ventricle volume (d=0.37, P=1.38× 10-9).
Each of these brain structures, except intracranial (P= 0.05, two-
tailed) and pallidum (P= 0.02, two-tailed) volumes, showed group
differences at the conservative Bonferroni-corrected threshold
of Po0.0056 (two-tailed). Group differences for putamen and
caudate volumes were not detectably different from zero. Analysis
without ICV as a covariate (model 2) did not substantially alter the
effect sizes, or their raking. Analyses of left and right hemisphere
volumes showed similar findings as for their mean; removal of age
and sex covariates (model 3) lowered all effect sizes (Supplemen-
tary Tables S1a and c). Heterogeneity of effect sizes, as measured
by the I2 statistic, was moderately high to high for all regions
(range: 68–87%). Effect sizes for each sample are provided in
Supplementary Figure S3.
Moderator analyses
Moderator analyses use meta-regressions, which examine the
effects of moderator variables on meta-analysis effect sizes using
regression techniques. Our moderator analyses found that sample
means for duration of illness and age were positively associated
with putamen (P= 0.002, P= 0.002, respectively) and pallidum
(P= 0.0002; P= 0.002, respectively) group contrast effect sizes. The
sample proportions of medication-naive patients were negatively
(P= 0.0004) associated with hippocampus group contrast
effect sizes (Table 2, Supplementary Tables S2a and m and
Supplementary Figure S4).
At an uncorrected statistical threshold (Po0.05), differences in
sample proportions of males (Sz−HV) were negatively associated
with accumbens (P= 0.007) and amygdala (P= 0.01) group
contrast effect sizes, sample proportions of patients treated with
second-generation antipsychotics were negatively associated with
lateral ventricle group contrast effect sizes (P= 0.04), sample
means of current chlorpromazine dose equivalents were positively
associated with lateral ventricle volume group contrast effect
sizes (P= 0.03), sample means for age of onset were negatively
associated with hippocampus group contrast effect sizes (P= 0.02),
sample means for PANSS-negative symptom severity were
negatively associated with lateral ventricle group contrast effect
sizes (P= 0.01) and scanner field strength (1.5/3 T) was negatively
associated with amygdala group contrast effect sizes (P= 0.03).
There were no detectable effects of proportion of typical/both
antipsychotics, or FreeSurfer version on any of the group contrast
effect sizes (all P40.05; Supplementary Tables S2a and m).
Power analyses
Our sample of 2028 individuals with schizophrenia and 2540
healthy controls provided 80% power to detect Cohen’s d effect
sizes of 0.084 at Po0.05 (two-tailed) and 0.108 at the conservative
Bonferroni-corrected threshold of Po0.0056 (two-tailed). Esti-
mated sample sizes needed, in each group, to achieve 80% power
to detect group differences at Po0.05 (one-tailed) across ROIs
range from 25 to 15 450 (Table 1).
DISCUSSION
In the largest cooperative analysis to date of brain MRI scans from
individuals with schizophrenia, we found that: (1) individuals with
schizophrenia, compared with healthy controls, have significantly
smaller hippocampus, amygdala, thalamus, accumbens and
ICVs, and significantly larger and pallidum and lateral ventricle
volumes; (2) the heterogeneity of effect sizes across samples was
moderately high to high; (3) putamen and pallidum volume
enlargements were associated with duration of illness and age
and (4) hippocampal volume deficits were more severe in samples
with a higher proportion of unmedicated patients.
The percent volume differences and effect sizes for ICV and
subcortical volume abnormalities were small to moderate (−4.10
to 18.24%, Cohen’s d=− 0.46 to 0.37); patients and controls
substantially overlapped in their distributions. The reported effect
sizes provide important information for power estimates in
schizophrenia imaging studies. The rank order and magnitude of
effect sizes across regions here agrees with the largest retro-
spective meta-analysis performed to date,11 which examined 38
brain structures, analyzed using a variety of different methods,
across 382 samples (317 studies) combining data from over 18 000
subjects. The biggest effect size was observed for smaller
hippocampus volumes (d=− 0.46) followed by larger lateral
ventricle volumes (d= 0.37) in patients versus controls. Despite
FreeSurfer’s relatively crude measure of intracranial brain volume,
based on registration scaling parameters, our findings agree with
other reports of smaller average intracranial brain volumes in
individuals with schizophrenia versus controls.4,11 This is consis-
tent with a role for disturbed brain development in the disorder.
The lack of detectable differences in caudate and putamen
volumes among individuals with schizophrenia on antipsychotic
medications also corroborates the findings by Haijma et al.11 who
Figure 1. Cohen's d effect sizes± s.e. for regional brain volume
differences between Individuals with schizophrenia and healthy
controls. Effect sizes for all subcortical volumes depicted were
corrected for sex, age and intracranial volume (ICV). The effect size
for ICV was corrected for sex and age. The number of independent
data points (NSz and NHV) for each region are listed in Table 1.
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observed smaller caudate volumes only in medication-naive
individuals with schizophrenia compared with controls.
The effect size estimates based on analyses excluding ICV
(model 2) as compared to including ICV (model 1) showed the
exact same pattern (Supplementary Tables S1a and c). As
expected from the lower ICV in patients compared with controls,
when not covarying for ICV, the negative effect sizes were slightly
more negative and the positive effect sizes were slightly less
positive. All effect sizes significant in model 1 remained significant
in model 2. Subcortical brain abnormalities are therefore largely
independent of intracranial volume. Removing age and sex from
the analysis rendered group contrasts for intracranial volume
nonsignificant and lowered subcortical volume effect sizes. This is
not surprising: removing covariates that explain variance increases
error variance, and reduces effect size.
Despite using similar imaging, quality assurance and analysis
methods, effect size heterogeneity across the samples was
moderately high to high for all regions (I2 range: 60–87%). Indeed,
the heterogeneity is even larger than that observed in the largest
retrospective meta-analysis.11 Although unexpected, this finding
may suggest that prospective meta-analyses, compared with
retrospective meta-analyses, show more true variation in effect
sizes owing to unselective reporting; the latter may show more
restricted variance owing to publication bias.
We found significant positive associations between duration of
illness as well as age and putamen and pallidum volume
exacerbations in schizophrenia. We also found that hippocampal
volume deficits showed a significant negative association with the
proportion of unmedicated patients. Meta-regression analyses
must be interpreted cautiously, owing to possible confounds (e.g.,
Simpson’s paradox26), but can be useful for hypothesis generation.
The positive association between duration of illness and the
volumes of the putamen and pallidum may reflect, in part, the
cumulative effects of antipsychotic medication treatment on basal
ganglia volumes; the association for caudate volume was also
positive, although not significant. Several longitudinal studies
report that antipsychotic treatments normalize caudate volume
deficits observed in medication-naive patients11 and increase
putamen volumes.27–32 Few studies report medication effects in
the pallidum. Caudate, putamen and pallidum volume–ICV ratios
may predict risperidone treatment effects in individuals with
schizophrenia.33 One retrospective meta-analysis suggests that
cumulative exposure to antipsychotic treatments is associated
with gray matter volume loss,34 but the field would benefit from a
prospective meta-analysis of longitudinal studies examining how
antipsychotic medications affect brain morphology over time,
especially because many studies only report data from a select set
of regions.
As duration of illness is highly correlated with age (r14 = 0.91,
Po0.001), we cannot exclude the possibility of disease-related
age effects on these regions. The latter interpretation is consistent
with independently replicated findings of larger pallidum volumes
in unmedicated, non-ill relatives of individuals with schizophrenia.
Hence, larger pallidum volumes may be associated with familial
(possibly genetic) liability35,36 (but see Honea et al.37 for a conflict-
ing finding, perhaps reflecting confounding factors). Longitudinal
Table 1. Cohen’s d effect sizes by region
Cohen's d P-value 95% CI % Difference N80 I2 NSz NHV
Hippocampus − 0.46 4.85 × 10−14 − 0.58 to − 0.34 − 4.10 25 71 2021 2531
Amygdala − 0.31 3.59× 10−7 − 0.43 to − 0.19 − 3.80 60 71 2024 2535
Thalamus − 0.31 1.31× 10−6 − 0.44 to − 0.18 − 2.74 60 74 2022 2533
Accumbens − 0.25 1.54× 10−5 − 0.36 to − 0.14 − 3.69 95 68 2018 2535
ICV − 0.12 0.05 − 0.24 to 0.00 − 0.30 425 73 2028 2539
Caudate 0.02 0.73 − 0.12 to 0.16 − 0.20 15 450 79 2024 2540
Putamen 0.08 0.36 − 0.09 to 0.25 0.20 962 86 2023 2536
Pallidum 0.21 0.02 0.04 to 0.39 2.28 136 87 2015 2538
Lateral ventricle 0.37 1.38 × 10–9 0.25 to 0.49 18.24 41 71 2028 2539
Abbreviations: CI, confidence interval; HV, healthy volunteer; I2, heterogeneity index; ICV, intracranial volume; N80, number of subjects needed in each group
for 80% power to detect significant group differences (Po0.05, one-tailed); NSz and NHv, the number of subjects with schizophrenia and healthy volunteers
included in the analysis, respectively. Group contrast (Sz−HV) effect sizes for mean ((left+right)/2) volumes controlling for age, sex and ICV. Effect size for ICV
controlling for age and sex.58 % Difference=mean weighted percent difference in volume between patients and controls ((Sz−HV)/HV) × 100%.
























Putamen 0.002 0.001 0.49 0.11 0.14 0.48 0.53 0.34 0.24 0.23
Pallidum 0.0002 0.002 0.58 0.69 0.52 0.68 0.15 0.96 0.82 0.10
Hippocampus 0.57 0.11 0.003 0.22 0.52 0.20 0.02 0.49 0.54 0.16
Lat. ventricle 0.30 0.16 0.28 0.65 0.04 0.03 0.28 0.01 0.43 0.61
Thalamus 0.84 0.32 0.43 0.96 0.81 0.08 0.09 0.15 0.72 0.87
Caudate 0.22 0.22 0.99 0.69 0.19 0.46 0.73 0.58 0.34 0.12
Amygdala 0.43 0.26 0.35 0.01 0.66 0.26 0.78 0.35 0.04 0.93
Accumbens 0.15 0.13 0.40 0.007 0.30 0.21 0.66 0.073 0.17 0.22
ICV 0.78 0.89 0.43 0.70 0.85 0.06 0.40 0.087 0.19 0.45
Abbreviations: CPZ, chlorpromazine; HV, healthy volunteers; ICV, intracranial volume; Sz, schizophrenia. Italic P-values are significant at the
Bonferroni-corrected threshold of Po0.0056. Bolded P-values are significant at a nominal P-value of Po0.05 (two-tailed).
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studies of clinically and/or genetically at-risk individuals are
needed to examine whether subcortical abnormalities, such as
larger pallidum volumes, reflect abnormal developmental trajec-
tories, in the absence of confounding factors (e.g., medications), as
suggested by abnormal associations of subcortical volumes with
age in adolescents at familial risk for schizophrenia.38
The finding that a larger proportion of unmedicated patients
was associated with larger hippocampal volume deficits is
surprising and warrants replication. This finding suggests that
untreated psychosis may be associated with more severe
hippocampus volume deficits and perhaps that hippocampal
volume deficits may be partially ameliorated by (atypical)
antipsychotic medications. This interpretation is supported by a
longitudinal study finding that schizophrenia patients on a
cumulative higher dose of atypical antipsychotics showed less
decrease or even small increases in hippocampus volumes over
time39 and findings of neurogenic effects of atypical but not
typical antipsychotics in the hippocampus subgranular zone.40
Notably, the 11 samples included in this meta-regression were
predominantly treated with atypical antipsychotics (sample-size-
weighted mean= 77%).
Our exploratory findings include smaller accumbens (P= 0.007)
and amygdala (P= 0.01) deficits among samples with larger
proportions of males in the schizophrenia compared with the
control sample. Most neuroimaging studies equate sex distribu-
tions between comparison groups and our findings indicate that
this may be particularly important when examining accumbens
and amygdala volumes. We also found that sample proportions of
patients treated with second-generation antipsychotics were
associated with smaller lateral ventricle volume enlargement
(P= 0.04); a finding perhaps consistent with observations of
smaller decreases in brain volumes in patients taking second-
compared with first-generation antipsychotic medications.41 In
contrast, current chlorpromazine dose equivalents were positively
associated with lateral ventricle volume exacerbations (P= 0.03);
the nature of this association remains to be determined. Most
unexpected, and in contrast to early findings,42 higher severity of
negative symptoms was associated with smaller lateral ventricle
volumes (P= 0.01). However, we believe that associations between
symptom severity and subcortical volumes are best studied within
site, followed by between site meta-analyses of the observed
within-site beta-weights in particular because no reliability for
symptom ratings was established between sites. Such analyses are
currently under development for cortical thickness and possible
findings for the subcortical volumes will be reported in the
planned manuscript. Also unexpected, given prior findings
showing opposite effects, is that higher mean age of onset was
associated with larger hippocampal volume deficits. This finding
may be consistent with larger hippocampus volume deficits in
patients with a longer duration of untreated psychosis;43 an
interpretation consistent with this study’s finding that hippocam-
pal deficits scale with the proportion of unmedicated patients. The
only methodological effect observed was that of larger amygdala
deficits at higher scanner field strength (3 versus 1.5 T). Brain
volume estimates may be more reliable at 3 versus 1.5 T, perhaps
due to reduced partial volume effects associated with smaller
voxels used at 3T;44 reliabilities for amygdala volumes at 1.5 and
3 T are comparable when the same voxel size is used.45
Strengths of this study include sample sizes of over 2018
patients and 2533 controls for each brain region (Table 1). For
measures other than intracranial and hippocampal volumes, this
study constitutes the largest meta-analysis of subcortical brain
volumes in schizophrenia to date. A second strength is the use of
similar image analysis, quality assurance and statistical analysis
methods across all brain regions from all 15 contributing studies.
Individual studies can maximize their statistical power by
restricting analyses to a smaller number of a priori regions of
interest, but in prospective meta-analyses participating sites are
free to include brain measures that would otherwise remain
unexplored.
A similar strategy to the one used in this study has been used in
an international mega-analysis of structural imaging in bipolar
disorder46 as well as in parallel ENIGMA—Bipolar Disorder (BD)
and Major Depressive Disorder Working Group studies, which
found significantly smaller hippocampus, amygdala and thalamus,
and significantly larger lateral ventricle volumes in bipolar
disorder47 and smaller hippocampus volumes in major depressive
disorder compared with controls with the latter effect mainly
present in individuals with recurrent major depressive disorder
and/or with an illness onset before age 22 years.48 Our prospective
meta-analyses strategy generates highly significant findings and
may be particularly useful in areas where study samples are
traditionally small or for which no comprehensive regional
assessment of brain morphology has been pursued—for example,
high-risk, medication-naive first-episode, longitudinal medication
studies, and comparisons across diagnostic boundaries.
This study has some weaknesses. We used the same image
analysis package across all samples (FreeSurfer), but a recent study
showed effects of FreeSurfer version, workstation vendor and
operating system version on brain volume and cortical thickness
estimates.49 Here, however, FreeSurfer version did not predict
effect sizes across studies for any of the regions examined.
Second, the overall sample included a higher proportion of males
in the patient (69%) compared with the control group (52%). It is
however unlikely that this discrepancy affects our findings
because (a) they replicate those of Haijma et al.11 who included
only studies matched for sex distribution, and (b) meta-regression
predicting effect sizes with group difference in the proportion
of males only showed a significant effect for the accumbens and
the amygdala, for which a higher proportion of males in the
schizophrenia compared with the control group was negatively
associated with group contrast effect sizes (P= 0.007 and P= 0.01,
respectively; Table 2 and Supplementary Tables S2a and m). Third,
our analysis only examined cross-sectional studies of individuals
with schizophrenia and healthy controls and only examined
subcortical and intracranial brain volumes. Fourth, apart from
disease-related biological factors, numerous confounding envir-
onmental factors can influence the volume of brain structures,
including fetal hypoxia,50 nutritional and hydration status,51–53
exercise,54 medications,11 smoking,55 cannabis use,41 social
isolation56 and the stress associated with severe mental illness.57
Parsing the contributions of such factors is an ongoing effort
within as well as outside the consortium. This is, however, a first
validation study for which significant efforts were put forward to
grow the consortium and develop a first robust analyses allowing
for validation of the approach. Plans for additional analyses of
patients’ relatives, relationship to more detailed clinical symptoms
and the study of additional brain measures (e.g., volume and
thickness of cortical ROIs) are under development.
In conclusion, this study shows a robust pattern of subcortical
brain abnormalities, suggests that that larger putamen and
pallidum volumes may be associated with duration of illness in
schizophrenia and suggests that treatment with predominantly
second-generation (atypical) antipsychotics may ameliorate hip-
pocampal volume deficits. The consistency between the reported
prospective meta-analysis findings and those from traditional
retrospective meta-analyses validate the prospective meta-
analysis approach. We are in the process applying similar methods
to cortical thickness and surface, as well as less well-studied
subcortical shape measures. For a review of ongoing efforts and to
join the collaborative see http://enigma.ini.usc.edu.
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